glp-1 receptor agonist type 1 diabetes randomized trial Agonists as Treatments for 2 Frontiers | Mechanisms of action
Description
10.1016/j.molmet.2019.09.010
Numerous studies have demonstrated that for every 10% increase in body mass index (BMI), the risk of developing OSAS increases by nearly six-fold (7, 8)
[DOI] [PubMed] [Google Scholar] Zhang X
Ryan DH, Lingvay I, Colhoun HMet al
Olof Eriksson, Director PET imaging at Antaros and Associate Professor at Uppsala University comments: We are very proud of this collaboration between Antaros Medical and Sanofi
